Every material Form 8-K Aspire-Lakewood Holdings, Inc. has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aspire-Lakewood Holdings dismissed Turner Stone & Company, LLP as its independent auditor on September 24, 2026, and the Audit Committee engaged CBIZ CPAs P.C. as its new auditor for the fiscal year ending December 31, 2026. Turner's prior report on the 2025 financial statements included a going concern explanatory paragraph, and the company disclosed material weaknesses in internal control over financial reporting.
Turner Stone & Company, LLP dismissed effective September 24, 2026
CBIZ CPAs P.C. engaged as new auditor for fiscal year ending December 31, 2026
Turner's report on 2025 financials included a going concern paragraph on substantial doubt
Company reports no disagreements with Turner and no other reportable events
Aspire-Lakewood Holdings, Inc. filed a charter amendment changing its name from Aspire Biopharma Holdings, Inc., effective September 8, 2026, and its Board authorized a $10 million common stock repurchase program effective September 9, 2026. The company said the buyback reflects its view that its share price does not reflect its financial strength, and it cited the newly acquired Dura Control Systems Corp. (DCSC) as support.
Board authorized a $10 million common stock repurchase program, effective September 9, 2026, with no expiration date and no required number of shares.
Name change to Aspire-Lakewood Holdings, Inc. was effective September 8, 2026; no stockholder approval was required and the CUSIP is unchanged.
The 8-K states the Nasdaq trading symbol remains ASPB, while the press release uses ASBP.
DCSC reported audited 2025 revenue of approximately $209.5 million and Adjusted EBITDA of $22.3 million; unaudited six months ended June 30, 2026 revenue was approximately $103.9 million and Adjusted EBITDA $10.5 million.
Aspire Biopharma Holdings, Inc. announced on September 8, 2026 that it has changed its corporate name to Aspire-Lakewood Holdings, Inc., effective when a Certificate of Amendment is filed in Delaware. The name change was approved by the board and stockholders, and the company says stockholders need not take any action.
Name changed from Aspire Biopharma Holdings, Inc. to Aspire-Lakewood Holdings, Inc., effective upon filing with the Delaware Secretary of State
Approved by the board and stockholders under Section 242 of the Delaware General Corporation Law
Release says the ticker ASBP is unchanged but also refers to a Nasdaq symbol ASPB, a discrepancy the filing does not resolve
No stockholder action required; stock certificates in the prior name remain valid
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aspire-Lakewood Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →